Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Study of TRX-920 for Patients With Advanced Solid Tumors
Details : TRX-920 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 22, 2023
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Bora Pharmaceuticals Partners with TaiRx
Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 27, 2022
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Details : Opdivo (Nivolumab) is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Opdivo
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 25, 2022
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
Details : CVM-1118 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2020
Lead Product(s) : Foslinanib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable